Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease

Lipoxins (LXs) protect against diabetic kidney disease (DKD) by resolving chronic low-grade inflammation, but the exact mechanism by which this occurs is not known. We investigated the effect of LXs on inflammatory markers and the recruitment of macrophages to the diabetic glomerulus by using LXs as both a preventive and delayed interventional treatment in streptozotocin-induced diabetic ApoE knockout mice. Protection against DKD was associated with reduced glomerular macrophage accumulation. LXs also attenuated the expression of VCAM1 in glomerular endothelial cells. LXs protect against DKD in part by a mechanism that reduces VCAM1 gene expression via H3K4 monomethylation on the VCAM1 gene.

Authors

Institutions

Publication Details

Journal
Diabetes
Published
2026-02-18
DOI
https://doi.org/10.2337/db25-0970
Primary Topic
Chronic Kidney Disease and Diabetes
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease

Catherine Tighe, Merlin C. Thomas, Assam El‐Osta, Patrick J. Guiry et al.
Diabetes
Chronic Kidney Disease and Diabetes
article

Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease

Catherine Tighe, Merlin C. Thomas, Assam El‐Osta, Patrick J. Guiry, Ramtin Radman, Muthukumar Mohan, Phillip Kantharidis, Kevin Gahan, Jun Okabe, Harikrishnan Kaipananickal, Madhura Bose, Victoria Priori, Cooper Me, Christos Tikellis, K C Sourris, K Jandeleit-Dahm, Eoin Patrick Brennan, Carolyn Chhor, Catherine Godson, Yvonne Zhang
article en

Abstract

Lipoxins (LXs) protect against diabetic kidney disease (DKD) by resolving chronic low-grade inflammation, but the exact mechanism by which this occurs is not known. We investigated the effect of LXs on inflammatory markers and the recruitment of macrophages to the diabetic glomerulus by using LXs as both a preventive and delayed interventional treatment in streptozotocin-induced diabetic ApoE knockout mice. Protection against DKD was associated with reduced glomerular macrophage accumulation. LXs also attenuated the expression of VCAM1 in glomerular endothelial cells. LXs protect against DKD in part by a mechanism that reduces VCAM1 gene expression via H3K4 monomethylation on the VCAM1 gene.

DiabetesVol. 75(4)
University College Dublin (IE), Baker Heart and Diabetes Institute (AU), Inserm (FR), Université Paris Cité (FR), Centre de Recherche sur l'Inflammation (FR), Monash University (AU)
Diabetes Australia Research Trust, Juvenile Diabetes Research Foundation United States of America, UCD Foundation, Diabetes Australia, Science Foundation Ireland, Monash University, Medical Research Council, National Health and Medical Research Council
Good health and well-being
Openalex Percentile: Top 58%
Chronic Kidney Disease and Diabetes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.